WO2008046559A1 - VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO - Google Patents
VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO Download PDFInfo
- Publication number
- WO2008046559A1 WO2008046559A1 PCT/EP2007/008866 EP2007008866W WO2008046559A1 WO 2008046559 A1 WO2008046559 A1 WO 2008046559A1 EP 2007008866 W EP2007008866 W EP 2007008866W WO 2008046559 A1 WO2008046559 A1 WO 2008046559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- estradiol
- daily
- combination
- dienogest
- phase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- estradiol valerate or 17 ⁇ -estradiol in combination with dienogest for oral therapy for maintenance and / or enhancement of female libido
- the invention relates to the use of estradiol valerate or 17ß-estradiol (estradiol) in combination with 17 ⁇ -cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) in a multi-phase or single-phase combination preparation for oral therapy for the preservation and / or Increase of female libido, possibly also in unity with an oral contraception.
- the total number of daily dose units of the multiphasic combination and a pharmaceutically acceptable placebo or the single-phase combination and optionally the pharmaceutically acceptable placebo-containing or placebo- and hormone-free daily dosage units correspond to 28 daily dosage units.
- Female libido is a very complex event, influenced by numerous hormonal and psychosocial factors. It has long been known that the onset of menopause can decrease the sexual desire of women. Here, the declining endogenous estradiol level and reduced androgen levels are discussed as reasons. It is less well known that taking conventional combined oral contraceptives and so-called progestin-only pills (POPs) may result in acquired loss / reduction of libido.
- the invention has for its object to find a means that realizes the preservation of the female libido, or their increase.
- estradiol valerate or estradiol in combination with 17 ⁇ -cyanomethyl-17-.beta.-hydroxyestra-4,9-diene-3one (dienogest) for the preparation of a multiphase combination preparation or single-phase combination preparation for oral therapy the maintenance and / or increase of the female libido solved.
- estradiol valerate or estradiol in combination with 17 ⁇ -cyanomethyl-17-.beta.-hydroxyestra-4,9-dien-3one (dienogest) for oral therapy for the maintenance or increase of the female libido optionally used in unit with an oral contraception containing a first phase of 2 daily doses of estradiol valerate at 3 mg or an equivalent dose of estradiol (less than 3 mg), a second phase from 2 groups of daily doses, the first group containing 5 daily doses of a combination of 2 mg estradiol valerate or an equivalent dose Estradiol (less than 2 mg) and 2 mg dienogest and the second group contains 17 daily doses of a combination of 2 mg estradiol valerate or an equivalent dose of estradiol (less than 2 mg) and 3 mg dienogest, a third phase consisting of 2 daily dose
- estradiol valerate or estradiol in combination with 17 ⁇ -cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for oral therapy for the maintenance or increase of the female libido libido optionally in unit with a oral contraception used, containing a first phase of 2 daily dose units of estradiol valerate at 3 mg or an equivalent dose of estradiol (less than 3 mg), a second phase of 2 groups of daily dosage units, the first group 5 daily doses of a combination of 2 mg Estradiol valerate or an equivalent dose of estradiol (less than 2 mg) and 3 mg dienogest and the second group of 17 daily doses of a combination of 2 mg estradiol valerate or an equivalent dose of estradiol (less than 2 mg) and 4 mg dienogest contains a third phase of 2 daily doses 1 mg estradiol valerate or an equivalent dose of estradiol (less than 1 mg) and another
- estradiol valerate or estradiol in combination with 17 ⁇ -cyanomethyl-17- ⁇ -hydroxyestra-4,9-diene-3-one for oral therapy for maintaining or increasing female libido, optionally used in unit with oral contraception, containing a first phase of 2 daily dose units of estradiol valerate at 3 mg or an equivalent dose of estradiol (less than 3 mg).
- a second phase of 2 groups of daily dose units comprising 5 daily doses of a combination of 2 mg estradiol valerate or equivalent estradiol (less than 2 mg) and 1 mg dienogest and the second group 17 daily doses of a combination of 2 mg estradiol valerate or equivalent dose of estradiol (less than 2 mg) and 2 mg dienogest, a third phase consisting of 2 daily doses with 1 mg estradiol valerate or equivalent estradiol (less than 1 mg) and another phase consisting of 2 daily doses of pharmaceutically acceptable placebo to produce a multi-phase combined preparation with a total number of 28.
- Estradiolvale- rat or Estrad iol in combination with equal to or less than 2 , 00 mg 1 7 ⁇ -cyanomethyl-1 7-.beta.-hydroxyestra-4,9-dien-3-one (dienog est) in a single-phase preparation for oral therapy for maintaining or increasing female libido, optionally used in unit with oral contraception.
- the single-phase combination contains 21, 22, 23, 24, 25, 26, 27 daily dose units with a constant amount of dienogest and estradiol valerate or dienogest and estradiol and 7, 6, 5, 4, 3, 2, 1 pharmaceutically acceptable placebo or placebo and hormone-free daily dosage units, so that the total number of daily doses equals 28. It is also advantageous to administer the single-phase preparation in the long-term cycle, wherein this
- Clinical trials are orally administered with a multiphasic combination of estradiol valerate and dienogest in which the first phase consists of 2 daily doses of estradiol valerate at 3 mg, the second phase consists of 2 groups of daily doses.
- the first group of this second phase consists of 5 daily doses of a combination of 2 mg estradiol valerate and 2 mg dienogest and the second group of 17 daily doses of a combination of 2 mg estradiol valerate and 3 mg dienogest.
- the third phase contains 2 daily doses of 1 mg estradiol valerate and another phase consists of 2 daily doses of pharmaceutically acceptable placebo.
- the total days of a multi-phase combination administration cycle and the pharmaceutically acceptable placebo are 28 days.
- the treatment (A) corresponded to the combination mentioned.
- the second treatment (B) corresponded to Miranova (standard OC)
- the trial included a pre-treatment cycle, 7 treatment cycles and a follow-up cycle.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200904273A UA97960C2 (ru) | 2006-10-20 | 2007-10-12 | ПРИМЕНЕНИЕ ЭСТРАДИОЛА ВАЛЕРАТА ИЛИ 17β-ЭСТРАДИОЛА В КОМБИНАЦИИ С ДИЕНОГЕСТОМ ДЛЯ ПЕРОРАЛЬНОГО ЛЕЧЕНИЯ ДЛЯ ПОДДЕРЖАНИЯ И/ИЛИ ПОВЫШЕНИЯ ПОЛОВОГО ВЛЕЧЕНИЯ У ОСОБИ ЖЕНСКОГО ПОЛА |
EA200900491A EA016631B1 (ru) | 2006-10-20 | 2007-10-12 | ПРИМЕНЕНИЕ ЭСТРАДИОЛА ВАЛЕРАТА ИЛИ 17β-ЭСТРАДИОЛА В КОМБИНАЦИИ С ДИЕНОГЕСТОМ ДЛЯ ПОДДЕРЖАНИЯ И/ИЛИ ПОВЫШЕНИЯ ПОЛОВОГО ВЛЕЧЕНИЯ У ОСОБИ ЖЕНСКОГО ПОЛА |
BRPI0717462-4A2A BRPI0717462A2 (pt) | 2006-10-20 | 2007-10-12 | Emprego de valerato de estradiol ou 17 beta- estradiol em combinação com dienogest na terapia oral para manutenção e/ou aumento da libido feminin |
AU2007312626A AU2007312626A1 (en) | 2006-10-20 | 2007-10-12 | Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido |
NZ576336A NZ576336A (en) | 2006-10-20 | 2007-10-12 | USE OF ESTRADIOL VALERATE OR 17-beta-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO |
CA2666829A CA2666829C (en) | 2006-10-20 | 2007-10-12 | Use of estradiol valerate or 17.beta.-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido |
EP07818937A EP2083827A1 (de) | 2006-10-20 | 2007-10-12 | VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO |
JP2009532710A JP2010506867A (ja) | 2006-10-20 | 2007-10-12 | 女性の性欲を維持、及び/又は亢進するための経口治療のための、吉草酸エストラジオール又は17β−エストラジオールとジエノゲストとの組み合わせの使用 |
MX2009004179A MX2009004179A (es) | 2006-10-20 | 2007-10-12 | Uso de valerato de estradiol o 17?-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina. |
IL198200A IL198200A (en) | 2006-10-20 | 2009-04-19 | Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido |
NO20091954A NO20091954L (no) | 2006-10-20 | 2009-05-19 | Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06022091 | 2006-10-20 | ||
EP06022091.0 | 2006-10-20 | ||
EP07009373A EP1930010A1 (de) | 2006-10-20 | 2007-05-10 | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
EP07009373.7 | 2007-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008046559A1 true WO2008046559A1 (de) | 2008-04-24 |
Family
ID=38809728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/008866 WO2008046559A1 (de) | 2006-10-20 | 2007-10-12 | VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO |
Country Status (17)
Country | Link |
---|---|
US (1) | US8349820B2 (de) |
EP (2) | EP1930010A1 (de) |
JP (1) | JP2010506867A (de) |
KR (1) | KR20090080989A (de) |
AU (1) | AU2007312626A1 (de) |
BR (1) | BRPI0717462A2 (de) |
CA (1) | CA2666829C (de) |
CO (1) | CO6160297A2 (de) |
CR (1) | CR10732A (de) |
EA (1) | EA016631B1 (de) |
GT (1) | GT200900090A (de) |
IL (1) | IL198200A (de) |
MX (1) | MX2009004179A (de) |
NO (1) | NO20091954L (de) |
NZ (1) | NZ576336A (de) |
SV (1) | SV2009003231A (de) |
WO (1) | WO2008046559A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
US20070088011A1 (en) * | 2005-10-17 | 2007-04-19 | Susan Zeun | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
US8153616B2 (en) * | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102247A2 (de) * | 2004-04-20 | 2005-11-03 | Schering Ag | Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4168068A (en) | 1969-07-22 | 1971-01-28 | Unisearch Limited | Improvements in or relating to oral contraceptives |
US3639600A (en) * | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
US3795734A (en) * | 1970-04-20 | 1974-03-05 | American Home Prod | Cyclic regimen of hormone administration for contraception |
US4066757A (en) * | 1973-03-26 | 1978-01-03 | Ortho Pharmaceutical Corporation | Oral contraceptive regimen |
DE2365103C3 (de) * | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | V erwendung von Hormonen zur Kontrazeption |
DE2431704A1 (de) | 1974-07-02 | 1976-01-22 | Asche Ag | Stufenkombinationspraeparate per kontrazeption |
DE2645307A1 (de) | 1976-10-05 | 1978-04-06 | Schering Ag | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen |
NL8001593A (nl) | 1980-03-18 | 1981-10-16 | Akzo Nv | Meerfasisch combinatiepreparaat voor orale anticonceptie. |
US4390531A (en) * | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
US4921843A (en) * | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
US4628051A (en) * | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4530839A (en) * | 1983-09-26 | 1985-07-23 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4616006A (en) * | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
DE3341638A1 (de) | 1983-11-17 | 1984-05-03 | Hermann Dr.rer.nat. 8000 München Heßlinger | Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol |
DE3347125A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
AU581486B2 (en) | 1985-12-30 | 1989-02-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
IE61236B1 (en) | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
CA2005933A1 (en) | 1989-01-09 | 1990-07-09 | Jesse Hipps, Sr. | Photohardenable composition containing five member aromatic group with imine moiety |
IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
DE4104385C1 (de) | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
DE4224534A1 (de) | 1992-07-24 | 1994-01-27 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
DE4308406C1 (de) | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Kombinationspräparat zur Kontrazeption |
DE4313926A1 (de) | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
DE4339934C2 (de) | 1993-05-07 | 1995-05-24 | Klaus Dr Med Umbreit | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
NL9301562A (nl) | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
US20050032756A1 (en) * | 1995-10-28 | 2005-02-10 | Michael Dittgen | Multistage preparation for contraception based on natural estrogens |
DE19540253C2 (de) | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
EP0917466B1 (de) | 1996-07-26 | 2004-10-06 | Wyeth | Orales contrazeptivum |
ES2223081T3 (es) | 1996-07-26 | 2005-02-16 | Wyeth | Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno. |
AU3888597A (en) | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Oral contraceptive |
CN1186023C (zh) | 1996-07-26 | 2005-01-26 | 惠氏公司 | 双相避孕方法及包含孕激素和雌激素组合物的药剂盒 |
US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
DE19654609A1 (de) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
US6987101B1 (en) * | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
DE19908762A1 (de) * | 1999-02-18 | 2000-08-31 | Jenapharm Gmbh | Verwendung von Dienogest in hoher Dosierung |
DE10045380A1 (de) | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
US6699820B2 (en) * | 2001-03-02 | 2004-03-02 | Hartmut Ulrich Bielefeldt | Method for making a superconductor with enhanced current carrying capability |
DE10294402D2 (de) * | 2001-09-29 | 2004-11-11 | Solvay Pharm Gmbh | Estrogen-Gestagen Kombinationspräparat und Anwendung |
EP1462106A1 (de) | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmazeutishe Zusammensetzungen und Kits enthaltend 17-Betaestradiol und Progesteron zur Behandlung von Gynäcologischen Storungen |
JP2007528358A (ja) | 2003-06-25 | 2007-10-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ジエノゲストを含んでなるホルモン置換療法および抑鬱療法 |
BRPI0516247A (pt) * | 2004-10-07 | 2008-08-26 | Duramed Pharmaceuticals Inc | métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente |
TW200726473A (en) | 2005-06-28 | 2007-07-16 | Wyeth Corp | Compositions and methods for treatment of cycle-related symptoms |
PT1787649E (pt) | 2005-10-13 | 2009-05-08 | Bayer Schering Pharma Ag | Utilização de valerato de estradiol em combinação com dienogest para a terapia oral da hemorragia uterina disfuncional em conjunto com uma contracepção oral |
US8153616B2 (en) * | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
-
2007
- 2007-05-10 EP EP07009373A patent/EP1930010A1/de not_active Withdrawn
- 2007-10-12 MX MX2009004179A patent/MX2009004179A/es unknown
- 2007-10-12 BR BRPI0717462-4A2A patent/BRPI0717462A2/pt not_active IP Right Cessation
- 2007-10-12 EP EP07818937A patent/EP2083827A1/de not_active Ceased
- 2007-10-12 NZ NZ576336A patent/NZ576336A/en not_active IP Right Cessation
- 2007-10-12 WO PCT/EP2007/008866 patent/WO2008046559A1/de active Application Filing
- 2007-10-12 AU AU2007312626A patent/AU2007312626A1/en not_active Abandoned
- 2007-10-12 JP JP2009532710A patent/JP2010506867A/ja active Pending
- 2007-10-12 CA CA2666829A patent/CA2666829C/en not_active Expired - Fee Related
- 2007-10-12 EA EA200900491A patent/EA016631B1/ru not_active IP Right Cessation
- 2007-10-12 KR KR1020097010244A patent/KR20090080989A/ko not_active Application Discontinuation
- 2007-10-17 US US11/873,595 patent/US8349820B2/en not_active Expired - Fee Related
-
2009
- 2009-04-19 IL IL198200A patent/IL198200A/en not_active IP Right Cessation
- 2009-04-20 GT GT200900090A patent/GT200900090A/es unknown
- 2009-04-20 SV SV2009003231A patent/SV2009003231A/es unknown
- 2009-04-20 CO CO09039733A patent/CO6160297A2/es unknown
- 2009-04-20 CR CR10732A patent/CR10732A/es not_active Application Discontinuation
- 2009-05-19 NO NO20091954A patent/NO20091954L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102247A2 (de) * | 2004-04-20 | 2005-11-03 | Schering Ag | Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens |
Also Published As
Publication number | Publication date |
---|---|
US8349820B2 (en) | 2013-01-08 |
KR20090080989A (ko) | 2009-07-27 |
EA200900491A1 (ru) | 2009-10-30 |
NO20091954L (no) | 2009-05-19 |
CA2666829C (en) | 2012-02-07 |
EP1930010A1 (de) | 2008-06-11 |
BRPI0717462A2 (pt) | 2013-12-24 |
AU2007312626A1 (en) | 2008-04-24 |
IL198200A0 (en) | 2009-12-24 |
EP2083827A1 (de) | 2009-08-05 |
JP2010506867A (ja) | 2010-03-04 |
SV2009003231A (es) | 2009-11-09 |
US20080125401A1 (en) | 2008-05-29 |
IL198200A (en) | 2012-10-31 |
EA016631B1 (ru) | 2012-06-29 |
CO6160297A2 (es) | 2010-05-20 |
NZ576336A (en) | 2012-03-30 |
CA2666829A1 (en) | 2008-04-24 |
MX2009004179A (es) | 2009-04-30 |
GT200900090A (es) | 2011-11-29 |
CR10732A (es) | 2009-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008046559A1 (de) | VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO | |
EP1011682B1 (de) | Mittel zur hormonalen kontrazeption | |
DE19705229C2 (de) | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen | |
DE69432752T2 (de) | Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält | |
US20050282790A1 (en) | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | |
DE202012012822U1 (de) | Empfängnisverhütungs-Set zur aufeinanderfolgenden täglichen Anwendung | |
EP1740163B1 (de) | Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens | |
DE3022337A1 (de) | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen | |
US20090137537A1 (en) | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | |
EP0885005B1 (de) | Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann | |
DE602004009288T2 (de) | Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose | |
EP1978970B1 (de) | Kontrazeptivum | |
DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
DE4405591C1 (de) | Mittel zur postmenopausalen Hormonsubstitution | |
DE102019115343A1 (de) | Vaginalring für die hormonelle Kontrazeption | |
DE102006003508A1 (de) | Arzneimittel umfassend eine Hormonkombination | |
DE69911955T2 (de) | VERWENDUNG VON DANAZOL ZUR BEHANDLUNG VON HYPOGONADISMUS IN MÄNNERn | |
EP1853273A1 (de) | Pharmazeutisches präparat zur kontrazeption | |
DE102004026669A1 (de) | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels | |
WO2007042110A1 (de) | Verfahren zur herstellung eines einphasigen pharmazeutischen präparates zur oralen therapie der dysfunktionellen uterinen blutung | |
WO2000048604A1 (de) | Verwendung von dienogest in hoher dosierung | |
SG175658A1 (en) | USE OF ESTRADIOL VALERATE OR 17β-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO | |
EP0966289A1 (de) | Budesonid zur behandlung von cholestatischen lebererkrankungen | |
WO1995022334A1 (de) | Mittel und verfahren zur postmenopausalen hormonbehandlung unter verwendung von gestagenen allein und anschliessend in kombination mit oestrogenen | |
DE9312236U1 (de) | Arzneimittelzusammensetzung zur Verlangsamung des Alterungsprozesses bei Männern |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780038944.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07818937 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007818937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009040519 Country of ref document: EG |
|
ENP | Entry into the national phase |
Ref document number: 2009532710 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 576336 Country of ref document: NZ Ref document number: 12009500741 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 198200 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2666829 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09039733 Country of ref document: CO Ref document number: MX/A/2009/004179 Country of ref document: MX Ref document number: CR2009-010732 Country of ref document: CR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200900491 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007312626 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097010244 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: A200904273 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2007312626 Country of ref document: AU Date of ref document: 20071012 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0717462 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090420 |